Daiichi Sankyo

Contact
daiichisankyo.co.jp
+81-3-6225-1111

Daiichi Sankyo Company, Limited

3-5-1, Nihonbashi-honcho, Chuo-ku
103-8426 Tokio
Japan
+81-3-6225-1111
daiichisankyo.co.jp
Contact
Profile News
Contact

About Daiichi Sankyo

Daiichi Sankyo Company, Limited, established in 2005 after the merger of two leading century-old Japanese pharmaceutical companies, is a global pharmaceutical innovator, continuously generating innovative drugs that enrich the quality of life for patients around the world. The company uses its cumulative knowledge and expertise in the fields of cardiovascular disease, cancer, metabolic disorders, and infection as a foundation for developing an abundant product lineup and R&D pipeline.

Read more about Daiichi Sankyo
Facts about Daiichi Sankyo
  • Focus : Manufacturer
  • Employees: 1001-5,000
  • Industry : Pharma

News about Daiichi Sankyo

Daiichi Sankyo

22-Nov-2024 | manufacturing

Daiichi Sankyo's investments in cancer drugs are taking shape

From Bavaria to the world: Daiichi Sankyo transfers technology for the development and production of antibody-drug conjugates to Germany

Read news
Daiichi Sankyo

02-May-2022 | business & finance

ViGeneron announces follow-on collaboration with Daiichi Sankyo to develop a novel gene therapy for prevalent eye diseases

ViGeneron GmbH, a next-generation gene therapy start up, announced a follow-on collaboration with Daiichi Sankyo Company, Limited to utilize ViGeneron’s ...

Read news
Daiichi Sankyo

19-Jan-2021 | business & finance

Start-up ViGeneron announces research collaboration with Daiichi Sankyo

Evaluate vgAAV for novel ophthalmic gene therapy

Read news
Daiichi Sankyo

28-Jul-2020 | business & finance

AstraZeneca and Daiichi Sankyo enter collaboration to develop and commercialise new antibody drug conjugate

Potential new medicine could redefine treatment standards in lung, breast and multiple other cancers

Read news
Daiichi Sankyo

18-Jul-2017 | science

Max Planck Society grants technology for cancer therapy

Daiichi Sankyo, Max Planck Innovation and Lead Discovery Center announce cancer research collaboration

Read news
Daiichi Sankyo

13-Nov-2014 | business & finance

Daiichi Sankyo Completes Ambit’s Acquisition

Daiichi Sankyo Company, Limited and Ambit Biosciences Corporation announced the results of Daiichi Sankyo’s tender offer to purchase all of the outstanding ...

Read news
Daiichi Sankyo

01-Oct-2014 | business & finance

Daiichi Sankyo to Acquire Ambit Biosciences

Daiichi Sankyo Company, Ltd. and Ambit Biosciences announced that they have entered into a definitive merger agreement under which Daiichi Sankyo will ...

Read news
Daiichi Sankyo

04-Sep-2013 | research and development

Daiichi Sankyo's Once-Daily Edoxaban Shows Efficacy and Superiority for the Treatment of Symptomatic VTE

Daiichi Sankyo Company, Limited (hereafter, Daiichi Sankyo) announced results from the global phase 3 Hokusai-VTE study of 8,292 patients with either acute ...

Read news
Show more news about Daiichi Sankyo

Here you will find Daiichi Sankyo Company, Limited